Blackstone Invests $125 Million in NantPharma, a NantWorks Company
11:36 EDT 24 Jul 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
California-based NantWorks, LLC, announced today that leading investment
firm Blackstone (NYSE: BX) has invested US$125 million in NantPharma, a
NantWorks company whose products include high quality, biologically
derived pharmac...
Other Sources for this Article
NantWorks
Jen Hodson, 310-405-7539
jhodson@nantworks.com
or
Blackstone
Peter
Rose, 212-583-5871
rose@blackstone.com
More From BioPortfolio on "Blackstone Invests $125 Million in NantPharma, a NantWorks Company"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
